前收市價 | 53.51 |
開市 | 53.76 |
買盤 | 53.48 x 400 |
賣出價 | 53.53 x 400 |
今日波幅 | 53.10 - 53.93 |
52 週波幅 | 50.27 - 67.36 |
成交量 | |
平均成交量 | 1,903,119 |
市值 | 12.013B |
Beta 值 (5 年,每月) | 0.69 |
市盈率 (最近 12 個月) | 16.21 |
每股盈利 (最近 12 個月) | 3.30 |
業績公佈日 | 2024年7月30日 - 2024年8月05日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 72.41 |
Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript April 30, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $0.746 EPS, expectations were $0.88. INCY isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello and welcome to Incyte First […]
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
Incyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%. The company is working on strengthening its pipeline to counter competition from newly approved drugs, which could impact sales of Jakafi, the company's biggest-selling drug, as it nears the loss of exclusivity later this decade. During the first quarter, the Delaware-based company gained worldwide exclusive global rights for Monjuvi, approved by the FDA for the treatment of certain kinds of blood cancer, from MorphoSys AG.